United Therapeutics Co. (NASDAQ:UTHR) Director Sells $192,081.30 in Stock

United Therapeutics Co. (NASDAQ:UTHR) Director Christopher Causey sold 510 shares of United Therapeutics stock in a transaction on Friday, November 1st. The shares were sold at an average price of $376.63, for a total transaction of $192,081.30. Following the completion of the transaction, the director now owns 3,675 shares in the company, valued at approximately $1,384,115.25. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

United Therapeutics Stock Performance

United Therapeutics stock traded up $2.78 during midday trading on Monday, reaching $376.80. 328,484 shares of the company were exchanged, compared to its average volume of 466,008. The company has a market capitalization of $16.82 billion, a price-to-earnings ratio of 16.55, a P/E/G ratio of 1.35 and a beta of 0.56. The firm’s 50-day simple moving average is $355.40 and its 200-day simple moving average is $317.82. United Therapeutics Co. has a 1 year low of $208.62 and a 1 year high of $379.51.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. The firm had revenue of $748.90 million during the quarter, compared to analysts’ expectations of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm’s quarterly revenue was up 22.9% compared to the same quarter last year. During the same quarter last year, the business posted $5.38 EPS. On average, analysts forecast that United Therapeutics Co. will post 24.85 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on UTHR. The Goldman Sachs Group lifted their price objective on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research report on Friday. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Bank of America lowered their price objective on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a research report on Thursday, August 1st. HC Wainwright lifted their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Morgan Stanley lowered shares of United Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their price objective for the company from $310.00 to $321.00 in a research report on Thursday, July 11th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and an average target price of $370.86.

Institutional Trading of United Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC grew its holdings in United Therapeutics by 1.1% in the 2nd quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company’s stock valued at $692,748,000 after buying an additional 22,978 shares during the period. LSV Asset Management grew its holdings in United Therapeutics by 82.5% in the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock valued at $307,837,000 after buying an additional 436,851 shares during the period. Dimensional Fund Advisors LP grew its holdings in United Therapeutics by 4.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 585,969 shares of the biotechnology company’s stock valued at $186,656,000 after buying an additional 22,683 shares during the period. Pacer Advisors Inc. grew its holdings in United Therapeutics by 19.6% in the 2nd quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company’s stock valued at $178,972,000 after buying an additional 92,240 shares during the period. Finally, Swedbank AB purchased a new stake in United Therapeutics in the 1st quarter valued at about $97,316,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.